Your browser doesn't support javascript.
loading
The role of immunomodulatory medications in the treatment of COVID-19.
Sattui, Sebastian E; Crow, Mary K; Navarro-Millán, Iris.
  • Sattui SE; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery.
  • Crow MK; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery.
  • Navarro-Millán I; Division of Rheumatology, Department of Medicine, Hospital for Special Surgery.
Curr Opin Rheumatol ; 33(5): 431-445, 2021 09 01.
Article en En | MEDLINE | ID: mdl-34397605
ABSTRACT
PURPOSE OF REVIEW Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies. RECENT

FINDINGS:

Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations.

SUMMARY:

Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article